| Prev Close | 225.60 |
| Day Low/High | 220.01 / 225.49 |
| 52 Wk Low/High | 215.78 / 344.00 |
| Avg Volume | 1.50M |
Biogen Inc. (BIIB)
220.06
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 184.45M |
| Market Cap | 41.61B |
| EPS | 21.60 |
| P/E Ratio | 8.41 |
| Div & Yield | N.A. (N.A) |
Latest News
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
High Flyers and Low Flyers
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
Now at the Plate, Your Pinch Hitter, Bret Jensen
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
Release Your 'Inner Spock' When Investing in Biotech Stocks
Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.
One Prescription for Uncertain Market? Gilead Sciences
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Biogen Could Rally in the Weeks Ahead
Buyers have returned in recent months and the stock could be ready to rise.
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Time to Get Back to What I Do Best: Shorting Stocks
After a five-year hiatus I'm ready to start throwing whammies in several directions.
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
Netflix Taking a Knife to a Gunfight with Disney, Apple, Plus Bitcoin
Bitcoin, the most famous of all crypto-currencies, has enjoyed something of a rebound of late.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Stepping Carefully Into the Second Quarter
The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
How I Use Options to Mitigate Risk and Create Income
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
Future Brightens for 2 Small Biotech Stocks
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Powell and Company Can Influence the Macro, but Not the Micro
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering
Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.
What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
Biogen Could Go Either Way - Mixed Indicators and Charts
Let's check to see what can be gleaned.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
Biogen's Slump Is Likely to Continue
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
